株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

米国における癌関連のMRおよび核/分子医学画像システム診断市場

U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems

発行 Medtech Insight 商品コード 316328
出版日 ページ情報 英文 180 pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=115.18円で換算しております。
Back to Top
米国における癌関連のMRおよび核/分子医学画像システム診断市場 U.S. Markets for Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems
出版日: 2014年10月01日 ページ情報: 英文 180 pages
概要

2014年には米国で約170万人が癌と診断され、約58万5,720人が癌で亡くなると推計されています。癌治療の進歩にも関わらず、癌は同国で心疾患に次いで2番目に多い死因となっています。現在、癌と戦うために、MRIやNMMI(核/分子医学画像)などの診断用画像モダリティを含むさまざまな手段が用いられており、医師がほとんど治療可能な段階で悪性腫瘍を検知することを可能にしています。2013年において、米国では癌に関連したMRI・NMMI処置が約1,510万件実施されました。同時に、これらの処置は約5億9,890万米ドルのシステム売上を生み出しました。これらの癌に関連した適応症向け診断システムの売上は、予測期間中に複利年率5.5%で増加し、2017年に7億8,010万米ドルに達すると予測されています。

当レポートは、米国における米国における新規の癌事例、有病率および癌による死亡などを含めた統計データを提供しており、概略下記の構成で取り上げております。

エグゼクティブサマリー

第1章 癌統計のアップデート

  • 癌細胞の獲得能力
  • 癌の進行に含まれるゲノム変化の目録
  • 癌の進行に関連するリスク因子
  • 癌のステージング
  • 新たな癌の事例、癌の有病率、および癌による死亡
  • 主な癌タイプの臨床・統計データ
    • 脳・その他の神経系癌
    • 乳癌
    • 結腸直腸癌
    • 腎臓/腎盂癌
    • 白血病
    • 肺/気管支癌
    • リンパ腫
    • メラノーマ
    • 口腔/咽頭癌
    • 卵巣癌
    • 膵臓癌
    • 前立腺癌
    • 甲状腺癌
    • 膀胱癌
    • 子宮癌

第2章 米国の癌関連MRおよびNMMI(核/分子医学画像)システム診断市場

  • MRIシステム:市場分析
  • NMMI(核/分子医学画像)システム:市場分析

第3章 企業プロファイル

  • Digirad Corporation
  • Esaote North America, Inc./Esaote SPA
  • GE Healthcare, Inc./General Electric Company
  • Hitachi Medical Systems America, Inc./Hitachi Medical Corporation/Hitachi LTD
  • ntraMedical Imaging LLC
  • NeuroLogica Corporation/Samsung Electronics America, Inc./Samsung Electronics Co LTD/Samsung Group
  • Neusoft Medical Systems Co LTD/Neusoft Corporation
  • Philips Healthcare, Inc./Royal Philips NV
  • Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  • Toshiba America Medical Systems, Inc./Toshiba Corporation
目次
Product Code: A416

It is estimated that nearly 1.7 million people in the United States (U.S.) will be diagnosed with cancer in 2014, and that approximately 585,720 will die from the disease. Despite advancements in oncology (the branch of medicine that deals with cancer), the disease remains the second-leading cause of death in the country after heart disease. Today, a constellation of methods are used in the fight against cancer, including diagnostic imaging modalities such as magnetic resonance imaging (MRI) and nuclear/molecular medicine imaging (NMMI), which allow physicians to detect malignancies at their most treatable stages.

In the U.S., approximately 15.1 million diagnostic oncology-related MRI and NMMI procedures were performed in 2013. Together, these procedures generated approximately $595.9 million in corresponding systems sales; it is expected that during the forecast period covered by this report, sales of these systems for diagnostic oncology-related indications will increase at a compound annual rate of 5.5%, reaching an estimated $780.1 million in the year 2017.

This dynamic, new report from Medtech Insight includes analyses of products, current/forecast markets, competitors, and opportunities in the U.S. diagnostic oncology-related MRI and NMMI systems arena.

Covered topics in this report include a statistical overview of cancer in the U.S. including cancer incidence and prevalence, cancer-related deaths, and cancer risk factors; MRI applications and indications; MRI computer-aided detection; MRI systems including bore-less, enclosed, flared-gantry, intraoperative, open, and wide-bore models; NMMI applications and indications; positron emission tomography (PET) and hybrid PET systems; radioisotope/radiopharmaceutical shortages; single-photon emission computed tomography (SPECT) and hybrid SPECT systems, total and diagnostic oncology-related MRI and NMI procedures volumes and market forecasts, among others.

Table of Contents

EXECUTIVE SUMMARY

  • i. Cancer Overview
  • ii. Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Systems Market
    • a. Magnetic Resonance Imaging Market Segment
    • b. Nuclear/Molecular Medicine Imaging Systems Market Segment
  • iv. Methodology
  • Exhibit ES-1: Estimated New Cases, Prevalence,and Deaths for Selected Types of Cancer
  • Exhibit ES-2: Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit ES-3: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit ES-4: Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit ES-5: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit ES-6: Magnetic Resonance Imaging Systems, Market Forecast, 2013-2018
  • Exhibit ES-6: Nuclear/Molecular Medicine Imaging Systems, Market Forecast, 2013-2018

1. CANCER STATISTICS UPDATE

  • 1.1. Acquired Capabilities of Cancer Cells
  • 1.2. Cataloging Genomic Alterations Involved in the Development of Cancer
  • 1.3. Risk Factors Associated with the Development of Cancer
  • 1.4. Cancer Staging
  • 1.5. New Cancer Cases, Cancer Prevalence, and Deaths Due to Cancer
  • 1.6. Clinical and Statistical Data for Selected Types of Cancer
    • 1.6.1. Brain and Other Nervous System Cancers
      • 1.6.1.1. Etiology
      • 1.6.1.2. Epidemiology
    • 1.6.2. Breast Cancer
      • 1.6.2.1. Etiology
      • 1.6.2.2. Epidemiology
    • 1.6.3. Colorectal Cancer
      • 1.6.3.1. Etiology
      • 1.6.3.2. Epidemiology
    • 1.6.4. Kidney/Renal Pelvis Cancer
      • 1.6.4.1. Etiology
      • 1.6.4.2. Epidemiology
    • 1.6.5. Leukemia
      • 1.6.5.1. Etiology
      • 1.6.5.2. Epidemiology
    • 1.6.6. Lung/Bronchus Cancer
      • 1.6.6.1. Etiology
      • 1.6.6.2. Epidemiology
    • 1.6.7. Lymphoma
      • 1.6.7.1. Etiology
      • 1.6.7.2. Epidemiology
    • 1.6.8. Melanoma
      • 1.6.8.1. Etiology
      • 1.6.8.2. Epidemiology
    • 1.6.9. Oral Cavity and Pharyngeal Cancers
      • 1.6.9.1. Etiology
      • 1.6.9.2. Epidemiology
    • 1.6.10. Ovarian Cancer
      • 1.6.10.1. Etiology
      • 1.6.10.2. Epidemiology
    • 1.6.11. Pancreatic Cancer
      • 1.6.11.1. Etiology
      • 1.6.11.2. Epidemiology
    • 1.6.12. Prostate Cancer
      • 1.6.12.1. Etiology
      • 1.6.12.2. Epidemiology
    • 1.6.13. Thyroid Cancer
      • 1.6.13.1. Etiology
      • 1.6.13.2. Epidemiology
    • 1.6.14. Urinary Bladder Cancer
      • 1.6.14.1. Etiology
      • 1.6.14.2. Epidemiology
    • 1.6.15. Uterine Cancer
      • 1.6.15.1. Etiology
      • 1.6.15.2. Epidemiology
  • Exhibit 1-1: Estimated New Cases, Prevalence, and Deaths for Selected Types of Cancer
  • Exhibit 1-2: Brain and Other Nervous System Cancers, Facts And Figures
  • Exhibit 1-3: Breast Cancer, Facts And Figures
  • Exhibit 1-4: Colorectal Cancer, Facts And Figures
  • Exhibit 1-5: Kidney/Renal Pelvis Cancers, Facts And Figures
  • Exhibit 1-6: Leukemia, Facts and Figures
  • Exhibit 1-7: Lung/Bronchus Cancer, Facts And Figures
  • Exhibit 1-8: Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-9: Non-Hodgkin Lymphoma, Facts and Figures
  • Exhibit 1-10: Melanoma of the Skin, Facts and Figures
  • Exhibit 1-11: Oral Cavity and Pharyngeal Cancers, Facts and Figures
  • Exhibit 1-12: Ovarian Cancer, Facts and Figures
  • Exhibit 1-13: Pancreatic Cancer, Fact and Figures
  • Exhibit 1-14: Prostate Cancer, Facts And Figures
  • Exhibit 1-15: Thyroid Cancer, Fact and Figures
  • Exhibit 1-16: Urinary Bladder Cancer, Fact and Figures
  • Exhibit 1-17: Cancer of the Uterine Corpus, Facts and Figures
  • Exhibit 1-18: Cancer of the Uterine Cervix, Facts and Figures

2. U.S. MARKETS FOR DIAGNOSTIC ONCOLOGY-RELATED MAGNETIC RESONANCE AND NUCLEAR/MOLECULAR MEDICINE IMAGING SYSTEMS

  • 2.1. Magnetic Resonance Imaging Systems, Market Analysis
    • 2.1.1. Technologies
    • 2.1.2. Procedure Volumes
    • 2.1.3. Products
    • 2.1.4. Market Forecast
    • 2.1.5. Competitive Analysis
  • 2.2. Nuclear/Molecular Medicine Imaging Systems, Market Analysis
    • 2.2.1. Technologies
      • 2.2.1.1. Imaging with Positron Emission Tomography Scanners
      • 2.2.1.2. Imaging with Gamma Cameras
      • 2.2.1.3. Imaging with Hybrid Devices
    • 2.2.2. Procedure Volumes
    • 2.2.3. Products
    • 2.2.4. Market Forecast
    • 2.2.5. Competitive Analysis
  • Exhibit 2-1: Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-2: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging, Combined Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-3: Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit 2-4: Diagnostic Oncology-Related Magnetic Resonance and Nuclear/Molecular Medicine Imaging Systems, Combined Market Forecast, 2013-2018
  • Exhibit 2-5: Magnetic Resonance Imaging, Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-6: 2014, Selected Magnetic Resonance Imaging Systems
  • Exhibit 2-7: Magnetic Resonance Imaging Systems, Market Forecast, 2013-2018
  • Exhibit 2-8: 2013, Magnetic Resonance Imaging Systems Market, Share by Supplier
  • Exhibit 2-9: Nuclear/Molecular Medicine Imaging, Procedure Volumes Forecast, 2013-2018
  • Exhibit 2-10: 2014, Selected Nuclear/Molecular Medicine Imaging Systems
  • Exhibit 2-11: Nuclear/Molecular Medicine Imaging Systems, Market Forecast, 2013-2018
  • Exhibit 2-12: 2013, Nuclear/Molecular Medicine Systems Market, Share by Supplier

3. COMPANY PROFILES

  • 3.1. Digirad Corporation
  • 3.2. Esaote North America, Inc./Esaote SPA
  • 3.3. GE Healthcare, Inc./General Electric Company
  • 3.4. Hitachi Medical Systems America, Inc./Hitachi Medical Corporation/Hitachi LTD
  • 3.5. IntraMedical Imaging LLC
  • 3.6. NeuroLogica Corporation/Samsung Electronics America, Inc./Samsung Electronics Co LTD/Samsung Group
  • 3.7. Neusoft Medical Systems Co LTD/Neusoft Corporation
  • 3.8. Philips Healthcare, Inc./Royal Philips NV
  • 3.9. Siemens Healthcare/Siemens Medical Solutions USA, Inc./Siemens AG
  • 3.10. Toshiba America Medical Systems, Inc./Toshiba Corporation

APPENDIX: COMPANY LISTING

Back to Top